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ABBREVIATIONS 
CAK  Cdk-activating kinase 
CDK  Cyclin-dependent kinase 
CKI  Cyclin-dependent kinase inhibitors 
ECM  Extracellular matrix 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
ERK  Extracellular signal regulated protein kinase 
GDP  Guanosine diphosphate 
GEF  Guanine-nucleotide exchange factor 
GTP  Guanosine triphosphate 
H2O2  Hydrogen peroxide 
MAPK Mitogen-activated protein kinase 
MEK  Mitogen/ERK kinase 
NES  Nuclear export sequence 
NLS  Nuclear localization sequence 
PI3K  Phosphatidylinositol-3 kinase 
PIP2  Phosphatidylinositol (3,4)-diphosphate 
PIP3  Phosphatidylinositol (3,4,5)-triphosphate 
PKB  Protein kinase B 
Rb  Retinoblastoma protein  
ROS  Reactive oxygen species 
RTK  Receptor tyrosine kinase 
RSK  Ribosomal S6 kinase 
TGF-ȕ Transforming growth factor- ȕ
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INTRODUCTION
Background
The liver is an excellent tissue for the study of growth regulation 
because of its ability to regenerate by a process of compensatory growth 
following surgical resection or toxic injury. Much of the investigation on 
the mechanisms of hepatic growth has been done in partially 
hepatectomized animals in vivo or in primary cultures of isolated 
hepatocytes. Furthermore, primary hepatocytes can be maintained in a 
serum-free medium with defined growth factors such as epidermal 
growth factor (EGF) [1, 2] and can respond to growth factor stimulation 
by expressing many of the same cell cycle regulatory proteins that are 
expressed in the liver and that drive liver regeneration in vivo.
Liver models are also well suited for studies of the early phases of 
carcinogenesis, because the growth of preneoplastic, cancer-prone 
lesions can be synchronously induced and are easily identifiable. 
Typically, carcinogen exposure results in p53 induction and growth 
inhibition. Initiated, preneoplastic cells are resistant to the cytotoxic 
effects of carcinogen exposure, compared to normal cells, and therefore 
escape this growth inhibition. Thereby, the cells may develop further 
towards neoplasia. Our laboratory has previously shown changes in the 
growth factor regulated phase of the cell cycle in carcinogen-exposed 
liver. In cultured hepatocytes, growth arrest was accompanied by altered 
signalling through the EGF receptor and a subsequent reduced nuclear 
accumulation of activated ERK [3]. Furthermore, carcinogen exposure 
led to delayed induction of cyclin D1 and abridged nuclear accumulation 
of cyclin dependent kinase 2 (CDK2) and CDK4 [4]. During these 
studies we decided to further explore the physiological mechanisms that 
regulate CDK2 and CDK4 nuclear trafficking in normal cells. The work 
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presented also describes growth factor- and stress activated ERK and its 
role in intracellular signalling. 
Intracellular signalling 
Hepatocytes from adult animals are constitutively resting cells, 
and growth factor stimulation is necessary to advance their cell cycle 
recruition and progression, until they become growth factor independent 
just prior to DNA synthesis. EGF, TGFĮ and HGF are all potent liver 
mitogens [5]. The former two bind to and activate the plasma membrane 
receptor tyrosine kinase EGF receptor (EGFR). The best characterized 
intracellular mitogenic signal thus initiated is the Ras-Raf-MEK-MAPK 
pathway [6, 7] (figure 1). The interaction between ligand activated 
EGFR and Shc/Grb2, either through Grb2 binding alone or as a 
preformed Shc/Grb2 complex, results in the recruitment of Sos to the 
plasma membrane [8-10]. Sos operates as a guanosine triphosphate 
(GTP) exchange factor converting an inactive guanosine diphosphate 
(GDP)-bound Ras to an active GTP-bound Ras [11, 12]. Ras is a 
membrane-localized G-protein, functioning as molecular switches in a 
variety of signalling pathways, including MAPK. There are three major 
isoforms of classical Ras; H-Ras, K-Ras and N-Ras, sharing a high 
degree of sequence homology [13]. 
Activated Ras mediates activation of the serine/threonine kinase 
Raf [14, 15]. The activation of Raf is complex and the process is not yet 
fully understood. Raf resides in the cytosol in an inactive state in 
complex with heat shock proteins and 14-3-3ȗ [16]. A binding site for 
Raf is created on the GTP-bound Ras upon ligand activation of EGFR. 
When bound to the Ras effector loop at the membrane, Raf then interacts 
through its zink finger domain with a second epitope on Ras, which must 
be prenylated [16, 17]. Raf is phosphorylated on serine and tyrosine 
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residues, and it is suggested that this stabilizes an open, active Raf 
configuration, enabling its release from Ras-GTP into the cytosol [17, 
18]. Raf then phosphorylates and activates the threonine/tyrosine kinases 
MAPK/ERK kinase (MEK) 1 and 2 by serine phosphorylation. MEK 
then activates the serine/threonine kinases MAPK ERK1 and ERK2 
through phosphorylation on threonine and tyrosine residues [19]. 
RTK
Figure 1: A schematic illustration of the MAPK pathway. Ligand-binding of 
Receptor Tyrosine Kinase (RTK) leads to autophosphorylation of the receptor 
and assembly of a signalling complex including Grb2, Sos and Ras. Activated 
Ras recruits Raf to the membrane. Raf then starts a cascade of phosphorylation 
through MEK and MAPK. Activated MAPK translocates to the nucleus where 
it phosphorylates a number of substrates. 
CM=cellular membrane, NM=nuclear membrane. 
Figure from http://jorde-lab.genetics.utah.edu/people/reha/Reha.html 
Upon activation, ERK can translocate to the nucleus and 
phosphorylate substrates important for growth progression [20]. The 
induction of cyclin D1 mRNA has most frequently been attributed to the 
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activation of ERK [21]. In most cases, activation of Ras-Raf-MEK-ERK 
cascade induces cyclin D1 gene expression. Several studies have shown 
that the induction of cyclin D1 requires only moderate ERK activity, but 
the activity must be sustained for several hours [22]. Sustained ERK 
signalling in resonse to integrin and RTK synergism [21] may therefore 
explain the joint growth factor plus ECM requirement for cyclin D1 
expression. However, it appears that MAPK pathway is not the only 
signalling pathway required for accumulation of cyclin D1 in G1-phase. 
Phosphatidylinositol-3 kinase (PI3K) is an another important 
modulator of cell survival, mitogenesis, cytoskeletal remodelling, 
metabolic control and vesicular trafficking in various cell systems [23]. 
PI3Ks are grouped into three classes (I-III) according to their substrate 
preference and sequence homology. Different classes of PI3K have 
distinct roles in cellular signal transduction, as do the different isoforms 
that can exist within each class. Class I PI3Ks are divided into two 
subfamilies, depending on the receptors to which they couple. Class 1A 
PI3Ks (PI3KĮ, ȕ and į) are activated by growth factor receptor-tyrosine 
kinases (RTKs), whereas class 1B PI3K (PI3KȖ) is activated by G 
protein-coupled receptors. Both type 1A and type 1B PI3Ks are also 
activated by Ras [24]. Class 1A PI3Ks are heterodimers composed of a 
p110 catalytic subunit and a p85 regulatory subunit. PI3K is activated by 
direct interaction between the p110 subunit and GTP-bound Ras [25], or 
by association of the p85 subunit to activated growth factor receptors 
[26, 27]. In rat hepatocytes, Gab2 has been identified as a key molecule 
responsible for EGF-induced PI3 kinase activation [28]. Following, all 
class 1 PI3Ks phosphorylate phosphatidylinositol (3,4)-diphosphate 
(PIP2), a constitutive membrane component, to create the lipid second 
messenger phosphatidylinositol (3,4,5)-triphosphate (PIP3) (figure 2). 
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Figure 2: A schematic illustration of the PI3K signalling pathway. Aktivation 
of Receptor Tyrosine Kinase (RTK) leads to autophosphorylation on tyrosine 
residues and transphosphorylation of adaptor proteins with SH2-domain. PI3K 
binds directly to phosphotyrosine residues on growth factor receptors or to 
adaptor proteins. Following activation, PI3K phosphorylates PtdIns-4,5-P2 to 
create the lipid second messanger PtdIns-3,4,5-P3 (PIP3). PIP3 phoshorylates 
PDK1. Activated PDK1 phosphorylates Akt, whereas Akt next phosphorylates 
a number of effector proteins, leading to complex events like cell cycle 
progression, survival or apoptosis. PTEN dephosphorylates PIP3 and therefore 
terminates PI3K signalling. 
Figure from http://www.benbest.com/health/cancer.html
The PIP3 signal is mediated by its binding to the plextrin 
homology (PH) domain of target proteins, which induces their 
membrane translocation and/or conformational changes. Known PIP3
targets are numerous and from a variety of enzyme classes, e.g. protein 
kinases, phospholipases and guanine-nucleotide exchange factors 
(GEFs). These PIP3 targets together regulate a huge list of essential 
cellular functions including transcription, translation, protein synthesis, 
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cell survival, cell cycle entry and the structure of the actin cytoskeleton 
[29]. PTEN (phosphatase and tensin homologue) dephosphorylates PIP3
and therefore terminates PI3K signalling [29]. 
The best known downstream target of PI3K is Akt, which 
transmit survival signals from growth factors [30-32]. Akt inhibits 
GSK3ȕ and FoxO transcription factors, which in turn control cell cycle 
regulators like cyclin D1 and p27Kip1. [33-37]. Inhibition of PI3K activity 
blocks both cyclin D1 mRNA and protein expression [38].
Requirement for PI3K for mammalian cell cycle progression was first 
recognized by studies adopting platelet-derived growth factor (PDGF) 
receptor mutants that lack phosphoacceptor sites required for binding of 
PI3K p85 [39, 40], as well as “add-back” mutants with selective 
restoration of these sites [41]. Inhibitors of PI3K, LY294002 and 
wortmannin, have also been shown to inhibit S-phase entry in a variety 
of cell types [42-45]. 
Cell-cycle progression and regulation 
Cell cycle progression is an exactingly regulated process where 
the fundamental task is to ensure that DNA is faithfully replicated and 
that sister chromatides are correctly segregated during mitosis. To ensure 
this, the cell has several cell cycle checkpoints. When the cells contain 
DNA damages that have to be repaired, cells activate DNA damage 
checkpoint that arrests the cell cycle. 
The periods of the cell cycle associated with DNA replication (S-
phase) and mitosis (M phase) are separated by gaps of varying lengths 
called G1 and G2 (figure 3). 
Progression of cells through the cell cycle is facilitated through 
the sequential activation of CDK-complexes [46, 47]. These complexes 
consist of a regulatory subunit (cyclin) and a catalytic subunit (CDK), 
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which are assembled and activated at specific points of the cell cycle. In 
many regards, the control of cell cycle progression by cyclins and CDKs 
is remarkably well conserved throughout eukaryotic species [48]. 
Figure 3: Regulation of the mammalian cell cycle. The periods of the cell 
cycle associated with DNA replication (S-phase) and mitosis (M-phase) are 
separated by gaps of various lengths called G1- and G2-phase. The G0 phase is 
a period in the cell cycle where cells exist in a quiescent state. To maintain 
genomic integrity, the cells are equipped with several cell cycle checkpoints 
(red arrows). 
Figure from homepage.mac.com/enognog/checkpoint.htm.
Cyclin-dependent kinases and cyclins 
Cyclin dependent kinases are the catalytic subunits of a large 
family of heterodimeric serine/threonine kinases whose best-
characterized members are involved in controlling progression through 
the cell cycle (figure 4). According to the latest versions of the human 
and mouse genomes, there are 11 genes encoding CDKs and 9 other 
genes encoding CDK-like proteins [49]. 
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Studies using sea urchin eggs identified a series of proteins that 
were synthesized and destroyed at each cleavage division. On the basis 
of this feature, these proteins were designed cyclins [50]. Analysis of the 
human genome has identified at least 29 genes encoding related proteins 
that share a conserved stretch of 150 amino acid residues termed cyclin-
box. This domain is formed by five helical regions and is responsible for 
binding to CDKs [49]. Transcriptional control [51] and ubiquitin-
mediated degradation [52] ensure the proper and irreversible timing of 
cyclin expression. Cyclin binding activates CDKs by inducing 
conformational changes in their structure [53, 54]. Cyclins have also 
been suggested to determine the substrate specificity of CDKs [55-58]. 
The G1 and S phases
Progression through G1 is regulated by a complex mechanism 
that can involve at least three CDKs – CDK4, CDK6 and CDK2 – and 
their regulators [59, 60]. Mitogenic signalling induces synthesis of the 
D-type cyclins and possibly the proper folding and transport of CDK4 
and /or CDK6 to the nucleus. Both the PI3 kinase – and MAPK 
pathways are required for hepatocyte cyclin D1 induction in response to 
mitogens [61]. 
In studies of mammalian cells, a clear theme has emerged 
concerning the role of the D-type cyclins during G1 phase. They seem to 
act as intracellular “sensors” of extracellular stimuli that promote 
proliferation [60, 62]. However, the role of the D-type cyclins appears to 
vary significantly between cell types. For example, whereas cyclin D1 is 
a pivotal mediator of G1 progression in many cell types including 
hepatocytes, it does not appear to mediate proliferation in lymphocytes, 
in which cyclin D2 appears to perform a similar function [63, 64]. 
The role of cyclin D3 is highly dependent upon the cellular context. It 
appears to promote cell cycle progression in some cell types and growth 
16
arrest or differentiation in others. In hepatocytes, cyclin D3 is expressed 
in quiescent cells and is only modestly responsive to EGF, insulin or PI3 
kinase signalling, suggesting that it does not play a critical role in 
regulating progression through G1 phase in response to these 
signals [61]. 
Positive regulation of CDK activity occur in two steps: 
phosphorylation on a central threonine residue (Thr160 and Thr172 for 
CDK2 and CDK4, respectively) by CDK activating kinase (CAK) and 
dephosphorylation of the threonine (Thr14) and tyrosine (Tyr15) 
residues by the Cdc25 phosphatase family [65, 66]. 
Active complexes of CDK4 or CDK6 and D-type cyclins 
phosphorylate members of the retinoblastoma (Rb) protein family, which 
includes pRb, p107 and p130. These proteins contain multiple sites for 
phosphorylation by CDKs, only some of which can be recognized by the 
CDK4-cyclin D and/or CDK6-cylin D complexes. The Rb family 
members have been the only demonstrated substrates for CDK4 for 
many years. However, recently it has been demonstrated that Smad3, a 
key mediator for TGF-ȕ antiproliferative responses, is a target for 
inhibitory phosphorylation by both CDK4 and CDK2 [67, 68]. 
Although the initial phosphorylation of Rb proteins is mediated 
by the CDK4–cyclin D and/or CDK6–cyclin D kinases, the irreversible 
inactivation of these proteins is presumed to be carried out by CDK2–
cyclin E. This process is believed to render cells independent of 
mitogenic signals and corresponds to the restriction point [59]. The 
restriction point has been defined as the stage during G1 in which cells 
no longer require mitogenic stimuli to undergo cell division. 
Progressive phosphorylation of Rb by CDK4/6-cyclin D and 
CDK2-cyclin E releases E2F and promotes S-phase entry [69, 70]. E2F 
is a transcription factor that regulates the expression of genes involved in 
S phase (reviewed in ref. [71]). Cyclin E itself is an E2F target gene and 
the cyclin E promoter contains defined E2F binding sites [72-74]. This 
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describes a growth factor dependent cyclin E induction in late G1 phase. 
Thus, as CDK2-cyclin E phosphorylates and inactivates Rb, cyclin E 
may reinforce its own expression through a positive feedback loop [75]. 
In addition to Rb, other proteins that regulate cell division are also 
CDK2-cyclin E substrates. NPAT/p220 is a transcription factor that 
controls cell cycle-dependent histone gene transcription, and 
phosphorylation of NPAT by CDK2-cyclin E stimulates histone mRNA 
synthesis [76, 77]. CDK2-cyclin E also phosphorylates p27Kip1,
CBP/p300 and centrosomal proteins like nucleophosmin and CP110 [78-
81]. Cyclin E cooperates with CDC6 as well, and this allow 
prereplication complexes to form during the G1-S transition [82]. 
Inactivation of pRb also participates in promoting the transcription of 
genes that are necessary for subsequent phases of the cell cycle, 
including those encoding the A-type and B-type cyclins. Although A-
type cyclins accumulate during S phase, synthesis of B-type cyclins is 
not evident until the G2–M transition. Indeed, current models propose 
that once CDK2 is no longer associated with cyclin E, it interacts with 
the newly synthesized A-type cyclins, A1 and A2. While cyclin A1 is 
limited to male germ cells, cyclin A2 is widely expressed [83, 84]. In 
cultured cells, cyclin A2 functions during both G1-S and G2-M phases 
[85-87]. Cyclin A2 can bind and activate CDK1 and CDK2 [88-90].  
CDK2–cyclin A complexes have been reported to phosphorylate 
numerous proteins that are thought to be required for proper completion 
and exit from S phase. These proteins include upstream regulators of 
Cyclin A (pRb), transcription factors (E2F1, B-Myb), proteins involved 
in DNA replication, DNA repair, histone modification, ubiquitine-
mediated proteolysis and cell cycle checkpoints (p53, p21Cip1, MDM2) 
[60]. 
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The G2 and M phases
At the end of S phase, A-type cyclins associate with CDK1. 
CDK2-cyclin A and CDK1-cyclin A complexes share several substrates 
and whether these complexes have differential roles during the S to G2 
phase remains obscure. During G2, A-type cyclins are degraded, 
whereas the B-type cyclins are actively synthesized. As a consequence, 
CDK1 binds to B-type cyclins – an association believed to be essential 
for triggering mitosis [91]. 
Figure 4: Regulation of the mammalian cell cycle. CDK4-Cyclin D 
complexes, together with CDK2-cylin E complexes, regulate G1 progression. 
In S-phase, CDK2-cyclin A complexes ensure transition to the G2 and M-
phase, whereas CDK1-cyclin B complexes, in M-phase, make the cycle 
complete. p16 and p21 are CDK inhibitors, which also regulate cell cycle 
progression.
Figure adapted from www.cicr.uq.edu.au/cancerBiology/cellCycle.html 
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CDK activating kinase
CDK7 together with cyclin H and the assembly factor MAT1 
forms the CAK complex, responsible for the activating phosphorylation 
of CDK1, CDK2, CDK4 and CDK6 [92-98]. CAK is located in the 
nucleus, mainly in coiled bodies [99, 100]. CDK7 activity is invariant 
during cell cycle, but levels and activity of CDK7 are both reduced in 
quiescent G0 cells [100, 101]. 
CDK inhibitors 
It is generally agreed that CDK inhibitors play a critical role in 
regulating cell cycle progression and exit during morphogenesis and 
differentiation and/or in maintaining cell quiescence [60, 102, 103]. 
Cyclin dependent kinase inhibitors (CKIs) have been assigned to one of 
two families based on their structures and CDK targets. The first class 
includes the INK4 proteins (inhibitors of CDK4), so named for their 
ability to specifically inhibit the catalytic subunits of CDK4 and CDK6. 
Four such proteins, p16INK4a [104], p15INK4b [105], p18INK4c [106, 107] 
and p19INK4d [108] are composed of multiple ankyrin repeats and bind 
only to CDK4 and CDK6, and not to other CDKs or to D-type cyclins. 
The second class of inhibitors includes p21Cip1 [109-114], p27Kip1 [115-
117] and p57Kip2 [118, 119] all of which contain characteristic motifs 
within their amino-terminal moieties that enable them to bind to cyclin 
and CDK subunits [120-125]. In hepatocytes, p21Cip1 is induced by 
growth factors during G1 phase, whereas p27 expression do not vary 
substantially during the cell cycle and is not dependent upon growth 
factors [126]. Based largely on in vitro experiments and in vivo
overexpression studies, CKIs of the Cip/Kip family were initially 
thought to interfere with the activities of cyclin D-, E- and A-dependent 
kinases. More recent work has altered this view and revealed that 
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although the Cip/Kip proteins are potent inhibitors of cyclin E and A-
dependent CDK2, they also act as positive regulators of cyclin D-
dependent kinases [60, 127, 128]. 
Nuclear translocation 
Little is known about the exact mechanisms that control nuclear 
import and export of cyclin-CDK complexes. CDK4-Cyclin D1 is 
imported into the nucleus in G1 phase, possibly by piggy-backing on the 
p21Cip1/p27Kip1 CDK-inhibitors [128, 129], and is then exported in S 
phase concomitant with phosphorylation by GSK3 and subsequent 
proteolysis [130].
The CDK2 sequence does not contain a classical nuclear 
localization signal (NLS), but CDK2 is a small protein and may thus 
enter the nucleus by diffusion. However, efficient nuclear translocation 
of CDK2 is likely to depend on association with a carrier protein. Its 
regulating partner, Cyclin E, contains NLS, thus cyclin E – CDK2 
complexes may translocate to the nucleus independently of p21Cip1
piggy-backing. Moreover, it has recently been suggested that the NLS of 
cyclin E is not functional [55, 131]. In addition, our studies suggest that 
nuclear translocation of G1 CDKs rely on p21Cip1 expression (submitted 
data).
The mechanisms responsible for promoting nuclear translocation 
of ERK and controlling is durability are largely unknown. In quiescent 
cells, ERK is located in the cytoplasm, in complex with its activator 
MEK [132]. Because of its nuclear export sequence, MEK localizes in 
the cytoplasm irrespectively of its activation state [133]. ERK itself does 
not contain a nuclear export sequence or a nuclear import sequence 
[134]. In spite of this, ERK accumulates in the nucleus following 
activation by a potent mitogen [20]. Nuclear export of dephosphorylated 
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ERK is also mediated by MEK, which shuttles in and out of the nucleus 
as a result of its nuclear export sequence [135]. 
Cellular growth arrest 
Growth arrest is a reversible halt of the cell cycle that occurs at 
either the G1/S or G2/M barrier. Growth arrest in G1 is a conserved 
response to a wide spectrum of cellular stresses like oxidative damage, 
radiation, heat stress, DNA damage due to carcinogens etc. Deregulation 
of the G1 checkpoint in cancer is rather a rule than an exception [47]. 
p53
The p53 gene, first described in 1979, was originally believed to 
be an oncogene, but genetic and functional data obtained ten years after 
its discovery showed it to be a tumor suppressor. Just as a car’s brakes 
regulate its speed, properly functioning tumor-suppressor genes act as 
brakes to the cycle of cell growth, DNA replication and division into two 
new cells [136].
The p53 protein is known to act biochemically as a transcription 
factor and biologically as a tumor suppressor. The biological functions of 
p53 are mainly mediated through transcriptional regulation of its 
downstream target genes. For example, p53-induced growth arrest is 
achieved primarily by transactivation of p21Cip1 for G1arrest (figure 5) 
and of 14-3-3s for G2 arrest [137]. 
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Figure 5: p53-mediated growth arrest in G1. Stress-activated p53 induces 
p21Cip1. p21Cip1 then bind to CDK-cyclin complexes and inhibits CDK-activity, 
a process that leads to G1-arrest. p53 is also able to inhibit CAK directly to 
inhibit cell cycle progression. 
Figure modified from www.eurekah.com/dbimages/blagosklonny_6_2.jpg 
Among the signals that activate the p53 protein, damage to the 
integrity of the DNA template is the most studied. Gamma or UV 
irradiation, alkylation of bases, depurination of DNA or reaction with 
oxidative free radicals all alter the DNA in different ways, and for each 
damaging agent, a different detection and repair mechanism is employed 
by the cell [139-141]. The activation of the p53 protein in response to 
stresses is mediated and regulated by protein kinases, histone acetyl-
transferases, methylases, ubiquitin and sumo ligases. In addition, the 
activated p53 protein appears to interact with a number of proteins that 
are important for its transcriptional activity such as promyelocytic 
leukaemia (PML) bodies and the Werner helicase [142-144]. 
CAK also has a role in response to DNA damage. Two different 
studies showed that p53 is a substrate of CDK7 in vitro [145, 146]. 
Phosphorylation of p53 enhanced the ability of p53 to bind to the 
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sequence-specific p53-responsive DNA element. In addition, a direct 
interaction between p53 and cyclin H has been observed both in vitro
and in vivo, and binding of p53 to CAK reduces CAK activity [138]. 
MDM2 prevents p53-dependent gene expression through diverse 
mechanisms. It inhibits transactivation by binding and occluding the p53 
N-terminal transactivating domain, preventing the interaction of p53 
with the basal transcription machinery [147-149]. Various stresses result 
in the acetylation of p53 by the histone acetyl transferases PCAF and 
p300/CBP; however, this too can be blocked by the assosoiation of p53 
with MDM2 [150-154]. In addition to these direct mechanisms of 
transcriptional inhibition, MDM2 can indirectly inhibit p53-dependent 
gene expression by ubiquitinating and degrading p53 [155, 156]. MDM2 
consists of several potential PI3 kinase binding sites of which Ser17 and 
Ser395 are phosphorylated in vitro and in vivo, respectively [157, 158]. 
Akt has been suggested to regulate the intracellular localization of 
MDM2 by phosphorylation on serines 166 and 186 [159]. 
Oxidative stress 
Oxidative stress may be defined as an imbalance between cellular 
production of reactive oxygen species (ROS) and antioxidant defence 
mechanisms [160]. ROS are defined as partially reduced metabolites of 
molecular oxygen and include superoxide anion (O2•-), hydrogen 
peroxide (H2O2) and hydroxyl radical (OH•). They are highly reactive, 
and may cause oxidative damage to cellular macromolecules [161]. H2O2
has a relatively long half-life and is soluble in both lipid and aqueous 
media, thus it easily diffuses to its cellular targets [162]. 
Growth factors and cytokines are capable of generating ROS that 
participate in cell signalling [161, 163, 164]. In agreement with this, 
Carmona-Cuenca et al showed that both EGF and TGF-ȕ increased ROS 
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production [165]. It is well established that membrane-localized NADPH 
oxidase is responsible for generation of ROS triggered by receptor 
binding of numerous peptide growth factors such as PDGP, HGF, 
insulin, VEGF and TNFĮ triggering cell proliferation, differentiation and 
apoptosis [166-168]. Rac-1 GTPase is the upstream signal enzyme for 
NADPH oxidase dependent ROS generation [169]. 
In normal hepatocytes, the major source of ROS production is 
toxic byproducts of oxidative phosphorylation in mitochondria. In 
addition, detoxification of hepatotoxins in the endoplasmatic reticulum 
or peroxisome compartments induces an endogenous production of ROS. 
A number of defence systems have evolved to combat the accumulation 
ionof ROS. These include various non-enzymatic molecules (e.g. 
glutathion, vitamins A, C and E and flavenoids) as well as enzymatic 
scavengers of ROS (e.g. superoxide dismutases (SOD), catalase and 
glutathione peroxide). When the cellular production of ROS exceeds the 
antioxidant capacity of the cell, oxidative damage of lipids, proteins or 
DNA will occur, resulting in oxidative stress, hepatic injury and possibly 
cell death [170]. 
It has been shown that oxidative stress leads to substantial 
activation of ERK and that growth factor receptors play an important 
role in mediating this effect. Expression of inactive mutant forms of 
various growth factor receptors reduces activation of ERK by oxidative 
stress [171], while overexpression of certain normal growth factor 
receptors results in enhanced activation of ERK by hydrogen peroxide 
[172].
Cell survival or apoptosis 
The balance between positive and negative signals determines the 
decision between life and death. An imbalance can result in diseases 
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linked to increased apoptosis or decreased cell survival. The extent of 
DNA damage and the level of different proteins contribute to the life or 
death decision-making process. 
In hepatocytes, growth and survival signals are initiated by EGF 
binding and mediated through the EGF receptor/Ras/Raf/MEK/ERK 
signalling pathway. In addition, PI3K provides a universal survival 
signal largely due to its ability to activate Akt, but PI3K is also able to 
block ROS production from the NAPDH oxidase activation, thereby 
promoting survival [165]. 
Some proteins in the cell cycle and apoptotic pathways, have dual 
roles following stimulation. Both p53, Ras, Akt, pRb, CDKs, cyclins and 
CKIs may induce cell proliferation, cell cycle arrest or cell death; the 
different outcomes depends on diverse variables [173]. 
The p53 protein is widely recognized as a “guardian of the 
genome” protein functioning during the cell cycle and apoptosis [174, 
175]. The factors and mechanisms underlying the decision to undergo 
growth arrest or apoptosis in response to p53 are not fully understood. 
The decision is likely complex and governed by multiple factors that 
depend on both extrinsic and intrinsic factors that are additionally cell 
type-specific. p53 induced apoptosis is mediated by activation of genes 
involved in two major apoptotic pathways: (1) the mitochondrial 
pathway, with genes such as BAX, NOXA, PUMA, p53AIP1, PIGs, and 
APAF-1; and (2) the death receptor pathway, with genes such as 
KILLER/DR5, FAS and PIDD. p53 regulates these processes by 
transactivating genes involved in different cellular functions, but p53 
also activates transcription-independent mechanisms of apoptosis [136, 
174, 176, 177]. It has also been demonstrated that MAPK signalling 
pathways, active in transformed cells, can differentially regulate the 
cellular response to p53 activation and suggest that the Ras/MEK 
pathway may be a specific determinant of the decision to undergo p53-
dependent apoptosis or G1 arrest [137]. 
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The anti-apoptotic effects of Ras can be mediated by up-
regulation of Bcl-2 and other anti-apoptotic members of the Bcl-2 family 
[178]. Downstream of Ras, activated Raf, MEK and ERK contribute to 
the inhibition of apoptosis by phosphorylating and inactivating Bad. 
Activation of PI3K by Ras also inhibits apoptosis by activating Akt, 
which also results in phosphorylation and inactivation of Bad [179]. Akt 
also phosphorylates and inactivates caspase-9 [180]. However, Akt can 
also affect cell survival by exerting its effect on the transcription factor 
NF-țB via phosphorylation of the NF-țB regulator IțB [181]. 
pRb inhibits cell cycle progression by interacting with 
transcription factors such as E2F. In addition pRb has been shown to 
suppress apoptosis. For instance, pRb-deficient embryos show defects in 
fetal liver haematopoiesis, neurogenesis and lens development, and 
extensive apoptosis was observed in these tissues [182, 183]. The 
mechanisms by which pRb/E2F influences apoptosis remain unknown, 
but E2F has been shown to induce the expression of the pro-apoptotic 
factor Apaf-1 and evidence suggests a role for E2F in apoptosis 
following DNA damage [184, 185]. E2F cannot induce apoptosis when 
pRb is coexpressed and pRb possibly has an anti-apoptotic effect 
through the inhibition of E2F [186, 187]. 
The role of CDKs and cyclins in cell proliferation is widely 
known, but contradictory results exist about the role of CDKs in 
apoptosis. Some studies report a pro-apoptotic activity for CDKs; they 
show requirement of activated CDKs during apoptosis of thymocytes 
[188, 189]. In addition, CDKs seem to be required for neuronal cell 
death [190]. Some apoptosis-inducing agents can cause induction of 
CDK1 and CDK2 activity prior to cell death [191]. Dominant negative 
mutants of CDK1, CDK2 and CDK3 suppress apoptosis, induced by 
staurosporine and TNF-Į [192]. Contrary, inhibition of CDK2 has been 
shown to protect thymocytes from apoptosis, mitochondrial changes and 
caspase activation [189]. 
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CDK inhibitors have been suggested to be indirectly involved in 
apoptosis through regulation of CDK. Improper regulation of CDK can 
send conflicting signals for cell division and cell cycle arrest. p21Cip1 can 
have anti or pro-apoptotic properties, for example. Overexpression of 
p21Cip1 inhibits radiation-induced apoptosis in human colorectal 
carcinoma cells, while an inducible expression of p21Cip1 sensitizes EJ 
tumor cells to mitomycin C-induced apoptosis [193, 194]. p27Kip1 may 
also have both pro- and anti-apoptotic effects [195-197]. 
TGF-ȕ is an important growth inhibitor and inducer of apoptosis 
in different cell types [198]. Apoptosis induced by TGF-ȕ has been 
linked to an oxidative stress process and production of ROS [199-201]. 
However, ROS may also induce adaptive responses through activation of 
proteins that mediate the survival of cells. ERK is an essential mediator 
of survival signals through phosphorylation of ribosomal S6 kinase 
(RSK), which positively influence the transcription of pro-survival genes 
[202]. A role for ERK in survival after ROS exposure has been shown in 
both cell lines and in hepatocytes [203-207]. In line with this, we found 
that ROS mediated adaptive responses to environmental stress through 
activation of ERK, providing increased cell survival [208]. 
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AIMS OF THE STUDY 
The background for the present work was studies in our laboratory 
showing changes in the growth factor regulated phase of the cell cycle in 
carcinogen-exposed liver. In cultured hepatocytes, growth arrest was 
accompanied by altered signalling through the EGF receptor and a 
subsequent reduced nuclear accumulation of ERK. Furthermore, 
carcinogen exposure led to reduced induction of cyclin D1 and abridged 
nuclear accumulation of CDK2 and CDK4. To clarify those mechanisms, 
it became apparent that we needed a better characterization of growth 
factor regulation of the G1 phase of the cell cycle in normal hepatocytes. 
Thus, we defined the following aims for this project: 
1. Define CDK2-cyclin E regulation of growth induction in normal 
cells.
2. Define p53 functions in normal cell proliferation. 
3. Characterize the regulation of ERK nuclear trafficking after growth 
factor- or stress activation. 
29
METHODOLOGICAL CONSIDERATIONS 
Detailed descriptions of the methods are given in the respective 
articles (appendices I-IV). The following methodological considerations 
will discuss the choice of model system and methods, some of their 
advantages and limitations, and describe some problems encountered 
during the course of the experimental work performed in this thesis. 
Cell cultures 
Cell cycle progression of normal hepatocytes was analysed by 
using a well-characterized in vitro model of primary rat hepatocytes 
stimulated to proliferate by addition of EGF [209, 210]. Primary 
hepatocytes isolated from adult liver are recruited from a resting G0 state 
into G1 phase of the cell cycle during cell isolation and plating [211]. 
Thus, these cells are effectively synchronized before receiving a further 
proliferative stimulus. Hepatocyte mitogens like EGF, TGFĮ and HGF 
effectively induce DNA synthesis in this model. Greater stimulation of 
DNA synthesis can be achieved in cultured hepatocytes from young, 
rather than old rats, apparently reflecting differences in signal 
transduction down-stream from growth factor receptors and/or in 
expression of genes regulating the cell cycle [212, 213]. Although mouse 
hepatocytes have the capacity to proliferate in the absence of growth 
factors in medium, proliferation activity of rat hepatocytes is tightly 
dependent on stimulation with mitogens. Thus, rat hepatocytes in culture 
represent a more appropriate model to study mitogen-dependent entry 
and progression along the cell cycle. However, under these conditions, 
the cells have limited lifespan in vitro (5-7 days) and usually die after 
one round of the cell cycle. The quality of the final suspension was 
checked by trypan blue exclusion as an indication of viability, and cell 
preparations with viability of 60-100 % were used. 
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Transfection
Primary hepatocytes are not easy to transfect. Thus, we tried 
several methods and transfection reagents to find an efficient and 
reproducible DNA-mediated gene transfer that did not interfere with the 
biological processes of interest. Viral transfection, calcium-phosphate 
and Lipofectamin, Transmessenger and DOTAP were evaluated 
considering transfection efficiency, toxicity and influence on 
proliferation. DOTAP, which is a special reagent for primary cells, 
showed highest transfection efficiency (30-60 %) and had little side 
effects and was therefore used in articles I, II and IV. 
To quantify transfection efficiency, a PEYFP-Mem Vector, which 
is a fusion protein consisting of the N-terminal 20 amino acids of 
neuromodulin and a yellow-green fluorescent variant of the enhanced 
green fluorescent protein (EGFP), was detected by fluorescence 
microscopy in viable cells. In some experiments it seemed like the 
majority of the cells were transfected. This might indicate that many 
cells express low levels of transfected genes. However, transfection 
efficiencies might be underestimated because of the high 
autofluorescence of hepatocytes. 
Immunological methods 
The high specificity of immunological methods makes them 
useful tools in cell biology. These methods are based on recognition 
between antigen epitope and antibody and were used to study relative 
protein levels, protein phosphorylation and cellular protein localization. 
The specificity of the antibodies used is very important for the reliability 
of the results. 
Western blotting was used to study protein levels and 
phosphorylation status. Protein dephosphorylation can happen fast. To 
inhibit dephosphorylation, lysis buffers contained inhibitors of 
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dephosphorylation in addition to inhibitors of protein degradation. When 
phosphorylation was examined, the samples were not stored, but 
immediately subjected to SDS-PAGE. 
We made use of nuclear fractionation and immunofluorescence 
microscopy studies to characterize the cellular localization of the various 
proteins. One of the major concerns with immunofluorescence 
microscopy is antibody cross-reactions. Immunological multi-staining 
requires crossover controls to ensure absence of immunological cross-
reactions. Nonspecific binding of antibodies cannot be totally eliminated, 
but it can be limited by preincubation of cells in blocking solution, 
antibody preabsorbtion and sufficient dilution of the antibody. The 
inherent possibilities of antibody cross-reactions, which in many cases 
are difficult to control for, underscores the need to supplement 
immunofluorescence microscopy with other techniques. We have 
therefore applied several different immunological methods to support 
our microscopy results. All antibodies used in immunofluorescence 
microscopy were tested by Western immunoblotting. 
Co-localization of proteins detected by confocal microscopy is 
only indicative of distribution to identical subcellular compartment and 
possible direct interaction. To avoid bleed-through from the two 
fluorochromes used in dual staining, the images were taken sequentially. 
By merging the red fluorochrome image with the green fluorochrome 
image, possible colocalization of the proteins are visualized as yellow 
signals.
Measurement of proliferation 
Primary hepatocytes can be maintained in a serum-free medium 
with defined growth factors, such as EGF, and respond to stimulation by 
expressing many of the same cell cycle regulatory proteins that are 
expressed in the liver and drives liver regeneration in vivo. To determine 
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the EGF dependent proliferation, we measured the incorporation of 3H-
thymidine into DNA by a liquid scintillation counter. 3H-thymidine
incorporated gives an accumulated measurement of the amount of cells 
in S-phase. To discriminate whether reduced thymidine incorporation 
was due to reduced proliferation or cell death, we used CPM per 
milligram protein as a measurement of proliferation. 
3H-thymidine incorporation is frequently used to measure 
hepatocyte proliferation, since the cells have a short lifetime in culture 
and are not viable throughout the mitosis. An alternative method might 
be flow cytometri, but this is difficult due to the high autofluorescence of 
hepatocytes. 
Cell death assay 
Survival mechanisms in hepatocytes exposed to H2O2 (article III) 
and TGF-ȕ (article IV) was determined by trypan blue exclusion assay in 
the first article and caspase assay in the latter. In necrosis, bleb rupture 
and breakdown of the plasma membrane permeability barrier leads to 
uptake of dyes like trypan blue that enters and label nuclei of nonviable 
cells. One of the major concerns with this method is that dead cells loose 
their adhesion capacity and might be washed away before counting. This 
can lead to a false high viability. 
In the caspase assay, cleavage of the fluorescent caspase-3 
substrate Ac-DEVD-amc was measured. Caspase-3 mediates apoptotic 
cell-death, thus this method might also give a false high viability since it 
does not detect caspase-independent cell death. 
33
SUMMARY OF ARTICLES 
Article I 
Activation of the p53-p21Cip1 Pathway is Required for CDK2 Activation 
and Proliferation in Primary Rat Hepatocytes. 
In this study we found that p53 and p21Cip1 were sequentially 
induced by EGF in primary rat hepatocytes, and that both proteins were 
regulated through PI3 kinase. p53 inactivation, by transfection with a 
dominant negative mutant resulted in inhibited CDK2- and CDK4 
nuclear accumulation, CDK activation and cell proliferation. These 
negative effects were neutralized by ectopic expression of p21Cip1. Thus, 
we demonstrated that EGF-induced p53-p21Cip1 was important for 
activation of both CDK2 and CDK4 and for proliferation in primary 
hepatocytes. 
Article II 
CDK2 Regulation through PI3K and CDK4 is Necessary for Cell Cycle 
Progression of Primary Rat Hepatocytes. 
The aim of this work was to clarify the molecular mechanisms 
involved in mitogen regulation of CDK2 in primary rat hepatocytes. We 
used two methods to knock out the CDK4 kinase activity in our cells. 
Indirectly, by inhibiting the PI3 kinase activity, and thus cyclin D1 
induction, and directly by overexpressing a kinase-defective mutant of 
CDK4. We found that cyclin E was induced in hepatocyte cultures 
independently of growth factor stimulation and PI3K signalling, but this 
was not sufficient for CDK2 nuclear translocation and pRb-
phosphorylation. We also demonstrated that CDK4 activity was essential 
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for CDK2 activation and for hepatocyte proliferation. In addition, our 
results suggested that PI3 kinase was involved in regulating CDK4 
activity, independently of cyclin D1 induction. These results are 
consistent with the hypothesis that contribution of CDK2-cyclin E 
complexes to pRb phosphorylation requires prior action by CDK4-cyclin 
D1 complexes. 
Article III
Cytoplasmic Retention of Peroxide-Activated ERK Provides Survival in 
Primary Cultures of Rat Hepatocytes. 
In this study we describe a role for cytoplasmically retained, 
redox-activated ERK in survival during oxidative stress in primary 
hepatocytes. We showed that H2O2 induced a dose-dependent activation 
of ERK that was transient but equally intense as phosphorylation 
induced by the growth factor EGF, both being MEK-dependent. 
However, whereas EGF-induced phosphorylated ERK accumulated in 
the nucleus and induced proliferation, H2O2-activated ERK was arrested 
in the cytoplasm and had no impact on cell proliferation. Instead, 
inhibition of H2O2-induced ERK activation with the MEK inhibitor 
U0126 reduced cell survival during ROS exposure significantly. Also, 
the cytoplasmic ERK substrate RSK, a known pro-survival protein, was 
activated and translocated to nucleus in H2O2-exposed hepatocytes. 
Article IV
Distinct Functions of H-Ras and K-Ras in Proliferation and Survival of 
Primary Hepatocytes Due to Selective Avtivation of ERK and PI3K
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In this study we showed that the isoforms H-Ras and K-Ras 
differentially activated the downstream effectors ERK and PI3K, thereby 
having distinct implications on proliferation and survival of primary 
hepatocytes. We observed that transient transfection of constitutive 
active H-Ras as well as constitutive active K-Ras, significantly reduced 
TGF-ȕ1-mediated apoptosis in primary hepatocytes. However, whereas 
H-Ras mediated survival through activation of ERK and PI3K, K-Ras 
induced survival relied on PI3K only. Also, H-Ras but not K-Ras 
mediated activation of the survival protein RSK, which is a known 
substrate of ERK. Further, transient transfection of constitutive active H-
Ras, but not K-Ras, potentiated EGF- induced proliferation and 
expression of dominant negative H-Ras, but not K-Ras reduced ERK 
phosphorylation and excluded ERK from the nucleus following EGF. 
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DISCUSSION OF RESULTS 
Our group has previously studied growth inhibition during early 
carcinogenesis, and our main focus has been to determine how this 
contributes to cancer development. In hepatocytes, DNA-damaging 
carcinogen exposure led to an extensive p53 induction and growth 
inhibition. However, p21Cip1 induction, which could have explained the 
growth inhibition, was not observed in cell cultures, and p21Cip1 was not 
found in complex with CDK2 in an in vivo, carcinogen-inhibited liver 
regeneration model [4, 214]. Instead, cytoplasmic retention of CDK2 and 
CDK4 appeared to be a central mechanism related to growth inhibition. 
Furthermore, previous studies indicated that EGFR-ERK1/2 signalling 
was altered in carcinogen-exposed hepatocytes [3], which possibly could 
explain the alterations in CDK2 and CDK4 regulation. Since our 
findings could not easily be explained by current concepts of hepatocyte 
growth regulations, we decided to further characterize growth factor 
regulation of CDK2, CDK4 and p53 in normal, proliferating 
hepatocytes. 
p53 dependent proliferation 
Generally, the major role of p53 is to induce cell cycle arrest, 
DNA reparation or apoptosis in response to cellular stress, particularly 
DNA damage [139]. However, new evidences support the concept that 
p53 might play key roles in extracellular matrix homeostasis and 
inflammation [215]. In addition, Inoue and coworkers have suggested 
that p53 is HGF regulated and indispensable for induction of hepatocyte 
proliferation [216]. 
Our studies of growth factor-induced cell cycle progression 
demonstrated an EGF-dependent induction of p53 and p21Cip1 in 
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hepatocytes. In line with previous data in other cell types [217], p53- 
p21Cip1 induction was a sequential event (article I). 
Previous studies have shown that PI3K regulates p53-Mdm2 
pathway on multiple levels under stress, induced by UV-radiation and 
proteasome dysfunction [218]. Recently, Bar and coworkers 
demonstrated that induction of p53 by Cisplatin in cultured cells required 
the presence of serum factors. In addition, the induction of p53 was 
blocked by the PI3K inhibitor LY294002, implicating the PI3K pathway 
as a critical mediator of the positive role of serum factors in p53 
activation [219]. Also in cultured hepatocytes, we found growth factor 
induction of p53 to be regulated through PI3K. 
When p53 was inactivated, by transfection with a dominant 
negative mutant or by the p53 inhibitor pifithrin-Į, hepatocyte 
proliferation was significantly reduced. This was in accordance with 
studies from Inoue et al. and implicated that growth factor induced p53 
was critical for cell cycle progression in hepatocytes [216]. 
Our observation that CDK2- and CDK4 nuclear accumulation and 
kinase activation was abolished when p53 was inhibited may explain 
why these cells did not proliferate. It is generally accepted that these two 
CDKs have to be transported to the nucleus to be activated and to 
inactivate pRb for further cell cycle progression [46, 220]. The 
mechanism behind nuclear transport of G1 CDK-cyclin complexes is not 
well understood, but piggy-backing on p21Cip1 has been suggested [128, 
129, 221]. Since hepatocytes with an inactive p53 did not express 
p21Cip1, wild type p21Cip1 was ectopically expressed in these cells. This 
coexpression almost completely abolished the negative effects of p53 
inactivation. Thus, our results demonstrated that p53 was involved in 
regulating CDK2- and CDK4 activity through p21Cip1 expression, 
initiated by an EGF induced PI3 kinase activity. Furthermore, the results 
showed that p21Cip1 was necessary for nuclear translocation of CDK2 
and CDK4, confirming its role as a piggy-backing nuclear transporter. 
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CDK2 regulation in G1 phase 
In carcinogen exposed hepatocytes, reduced induction of cyclin 
D1 and abridged nuclear accumulation of CDK2 and CDK4 was 
observed [4]. Based on these findings and our observations in article I, 
we decided to further explore the physiological mechanisms that regulate 
CDK2 and CDK4 nuclear trafficking in normal cells. 
During G1 phase in most experimental systems, the D- and E-type 
cyclins are induced and bind to their respective CDK partners to form 
active pRb kinases [222, 223]. In many cell types, cyclin D1 is the first 
cyclin to be up-regulated by growth factors during G1 phase. In 
hepatocytes, it has been reported that cyclin D1 induction corresponded 
in time with passage through the restriction point [126, 224, 225]. 
Previous studies have suggested that cyclin D1 plays an important role in 
hepatocyte proliferation [1, 38, 126, 225-228]. In accordance with 
Rickheim and coworkers we found that PI3K activation was required for 
hepatocyte cyclin D1 expression in response to mitogens [61]. On the 
other hand, cyclin E expression was detectable in the absence of growth 
factor, and its induction was not dependent upon an active PI3K (article 
II). In line with previous studies, we observed three cyclin E isoforms, 
and the two lower forms were up-regulated after EGF-stimulation [126]. 
Since PI3K inhibition abolished cyclin D1 induction, we expected 
CDK4 to be retained in the cytoplasm, even after EGF-stimulation. Our 
observations that both CDK4 and CDK2 was retained in the cytoplasm, 
implicated that mitogen-induced CDK2 nuclear translocation was 
dependent on an active PI3K. If this effect was mediated through CDK4 
activity or not was explored by overexpression of a dominant negative 
mutant of the protein. Mutant CDK4N158 contains an Asp-to-Asn 
mutation at amino acid residue 158, a position conserved in all cyclin 
dependent kinases. This residue is involved in the binding of Mg2+-ATP,
a necessary step for enzymatic activity of these kinases. It has been 
demonstrated in both insect cells and Rb-/- 3T3-cells that CDK4-
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inactivation lead to delayed cell cycle entry after serum starvation [229, 
230]. One way to verify that CDK4 activity is inhibited might be 
Western blotting with a Thr172-phospho-specific antibody. Such an 
antibody has been used in a recent study [231], but this was just a test 
preparation which is currently not commercial. Thus, inhibition of 
CDK4 activity was confirmed by showing reduced pRb phosphorylation 
at a CDK4-specific site (Thr826). In hepatocytes with an inactive CDK4 
kinase, we also demonstrated reduced Thr160-phosphorylation of CDK2 
and reduced pRb phosphorylation at a CDK2-specific site (Ser807/811). 
This was confirmed by data which showed that after CDK4 inactivation, 
the CDK2-cyclin E complex was retained in the cytoplasm. 
Correspondingly, we also found proliferation of these cells to be 
significantly reduced. It is generally accepted that both CAK and pRb 
are located in the nucleus, thus if CDK2 is retained in the cytoplasm, it 
can neither be activated by CAK nor function as a pRb kinase. From our 
observations in cells with an inactive CDK4, we then demonstrated that 
CDK2 nuclear accumulation and CDK2 kinase activity are dependent on 
a prior CDK4 activity. 
Lately, it has been an ongoing discussion whether mammalian 
cells need both CDK2 and CDK4 kinase activity for induction of S-
phase [232-238]. Other CDKs may compensate for the ablation of a 
particular cyclin-CDK complex in the context of knock-out mice. 
Whether this can occur if CDKs are knocked out after cellular 
differentiation remains unexplored. In cultured cells, it has been 
suggested that phosphorylation of pRb by CDK4-cyclin D1 initiates a 
subsequent round of phosphorylation of the tumor suppressor which is 
completed by CDK2-cyclin E in late G1 phase [239, 240]. This is in 
accordance with our data and suggests that CDK4 and CDK2 do not 
have overlapping functions in differentiated hepatocytes.
Because cyclin D1 is up-regulated in many human malignancies, 
the response to its overexpression has been studied extensively in cell 
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culture systems. In general, cyclin D1 alone does not promote cell cycle 
progression in the absence of mitogen, but it shortens the duration of G1 
phase in response to growth factors [60]. However, Nelson and 
coworkers have demonstrated that transient expression of cyclin D1 was 
sufficient to promote hepatocyte replication and liver growth [126, 227]. 
Conversely, we found that ectopic cyclin D1 expression did not induce 
CDK4 nuclear translocation, CDK2 activation or proliferation in the 
absence of growth factor. EGF-stimulation through PI3K was required 
even in this situation. Whether these differences reflects variations 
between our cell culture model and liver regeneration in an intact organ, 
or can be attributed to the adenoviral transfection method applied in the 
latter, remains unresolved. Our observations indicated that in addition to 
cyclin D1 induction, PI3K activity was necessary for translocation of 
CDK4- cyclin D1 complexes to the nucleus, and that this process was a 
prerequisite for nuclear translocation and functional activation of CDK2. 
In our p53-studies (article I), we found PI3K-dependent p21Cip1
expression important for CDK4 and CDK2 nuclear translocation. 
Therefore, we explored if overexpression of both p21Cip1 and cyclin D1 
was sufficient for CDK nuclear translocation or to initiate proliferation 
in our system. Preliminary data did not show proliferation in cells 
cotransfected with wild type p21Cip1 and wild type cyclin D1 in the 
absence of EGF, nor could CDK4 or CDK2 nuclear accumulation be 
observed (unpublished results). Thus, growth factor receptor signalling 
seemed to have additional effects critical in hepatocyte proliferation than 
cyclin D1 and p21Cip1 induction. 
Also, in the light of article I, we have cotransfected hepatocytes 
with wild type p21Cip1 and dominant negative CDK4. Preliminary data 
from these studies showed CDK2 nuclear accumulation and increased 
EGF-induced proliferation, compared to CDK4N158 transfected cells. 
Furthermore, we have lately observed reduced p53 induction in CDK4 
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inactivated hepatocytes. This might indicate that the effect of CDK4 
kinase activity on CDK2 is to induce p21Cip1.
Considering the conclusions in article I and II and the preliminary 
results described above, we suggest that PI3K-dependent CDK4 activity 
is necessary for p53- p21Cip1 induction, and that p21Cip1 is essential for 
the subsequent CDK2 nuclear translocation and activation. 
ERK in survival and proliferation 
Our group has earlier found that ERK do not translocate to the 
nucleus in carcinogen-exposed hepatocytes. Thus, the mechanisms 
regulating ERK nuclear trafficking in normal hepatocyte proliferation 
and during hepatocyte stress appeared to be relevant to early 
carcinogenesis.
Oxidative stress by ROS may cause severe damage and cell death. 
However, ROS may also induce adaptive responses through activation of 
proteins that mediate survival of cells. Particularly, a role for ERK in 
survival after ROS exposure has been shown both in cell lines and in 
primary hepatocytes [203-207]. Whether ERK is activated in a highly 
regulated manner or through interference with growth regulatory 
pathways is still unknown. We therefore studied the potential role of 
ERK during adaption of hepatocytes to oxidative stress in a hydrogen 
peroxide environment. H2O2 has been suggested to act as a paracrine 
mediator of apoptosis and has widely been used as a model of exogenous 
oxidative stress. In accordance with earlier findings [203, 204], we found 
a strong activation of ERK during H2O2 exposure. We also showed that 
this ERK-activation was independent of an active EGFR kinase activity. 
Thus, H2O2 can activate ERK directly or via upstream activators. 
MEK is the upstream activator of ERK in the signalling pathway 
from EGF receptor. In quiescent cells, ERK is located in the cytoplasm 
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where MEKs can serve as cytoplasmic anchors for ERK through direct 
binding interaction. Upon mitogen stimulation, the MEK-ERK 
association is disrupted and a proportion of ERK translocates to the 
nucleus [132]. Several studies show activation of MEK after ROS 
exposure. Also in hepatocytes, we found MEK to be the activator of 
ERK. However, ERK did not accumulate in the nucleus after H2O2
exposure, as seen after EGF stimulation. To exclude the possibility of a 
rapid export of the MEK/ERK complex, H2O2 exposed cells were 
pretreated with leptomycin B, a specific inhibitor of CRM1/exportin. 
Also in this case, ERK was exclusively located in the cytoplasm. Thus 
ERK activated by H2O2 did not enter the nucleus, but was arrested in the 
cytosol.
Specific intracellular localization of ERK has been shown to 
determine cell faith. Generally, ERK trapped in the cytoplasm blocks 
DNA synthesis and cell proliferation, whereas forcing an active ERK 
into the nucleus promotes proliferation and oncogenic transformation 
[241-243]. Activated ERK can provide survival through several 
downstream mediators, including RSK [202], which neutralizes the pro-
apoptotic protein Bad [244]. We found a strong reduction in the survival 
of hepatocytes when activation of ERK was inhibited. Second, we found 
RSK to be activated, via ERK, by both oxidative stress and growth factor 
stimulation. Activated RSK was located in the nucleus. Thus, to 
conclude this article we hypothesized that survival in hepatocytes was 
mediated by redox-activated ERK from the cytoplasmic compartment 
through activation and nuclear transport of RSK. 
Considering the results in article III, we next explored one of the 
upstream activators of ERK, Ras. Ras has been suggested as an upstream 
H2O2 acceptor [206]. By activating both the MAPK signalling cascade 
and the PI3K pathway, Ras has a role in cell proliferation as well as in 
inhibition and promotion of apoptosis [245]. 
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TGF-ȕ1 plays an important role in mediating hepatocyte death in
vivo, thereby controlling liver size [246]. TGF-ȕ1 does not activate ERK 
or PI3K [247], therefore we used TGF-ȕ1-exposure as a model to induce 
cell death. The apoptotic process induced by TGF-ȕ1 is mediated by 
ROS. Moreover, it includes the activation of caspases 2, 3, 7 and 8 [248]. 
Several growth factors, including EGF, are able to oppose the apoptotic 
process. In agreement with previous studies, we found that both ERK- 
and PI3K activation suppressed TGF-ȕ1–induced apoptosis [247, 249]. 
However, PI3K had a more potent anti-apoptotic effect on TGF-ȕ1-
exposed primary hepatocytes. 
The C-terminal portion of Ras proteins, encompassing the last 25 
amino acids, is unique for each isoform and has therefore been termed 
the hypervariable region (HVR). The function of HVR is to mediate the 
association of Ras proteins with cellular membranes. This function is 
accomplished through post-translational modifications of HVR. Whereas 
H-Ras undergoes both farnesylation and palmitoylation, K-Ras 
undergoes only a single lipid modification – farnesylation [250]. Several 
studies have reported that H-Ras is retained in the endosomes to a much 
higher extent than K-Ras, and that the latter recycles faster to the plasma 
membrane due to ineffective sorting into the early endocytic 
compartment [251, 252]. We found endogenously expressed H-Ras and 
K-Ras internalized and co-localized with EGF receptor in endosome-like 
compartments after stimulation with EGF, suggesting an equal 
endosomal sorting of the two isoforms. 
Recently, it has been suggested that the two homologues H-Ras 
and K-Ras may have different biological effect. When overexpressed in 
COS-cells, K-Ras has been reported to be a more potent activator of the 
ERK pathway, whereas H-Ras was a more potent activator of PI3K 
[253]. However, contradictory results have been reported, showing that 
oncogenic K-Ras expressed in vivo did not activate the Raf/ERK 
pathway in unstimulated cells [254]. In accordance with the latter, we 
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found that expression of constitutive active K-Ras (K-Ras V12) did not 
activate ERK in unstimulated cells. Conversely, in the absence of EGF, 
expression of constitutive active H-Ras led to phosphorylation, but not 
nuclear translocation of ERK. Still, H-Ras is critical for ERK 
phosphorylation and nuclear transport, since the dominant negative 
mutant (H-Ras N17) abolished EGF induced ERK nuclear accumulation. 
To promote cell cycle progression, ERK has to be activated and 
translocated to the nuclear compartment [241]. However, Ras-
independent pathways also need to be initiated before cells respond 
mitogenically to EGF [255]. This is in accordance with our findings that 
constitutive active H-Ras, or the combination of constitutive active H-
Ras and K-Ras, were not enough to mimic growth factor stimulation and 
induce cell cycle progression. 
Toulany and his group have shown that K-Ras mediate radio-
resistance in carcinoma cell lines by activating PI3K [256]. In line with 
this, we found that K-Ras mediated an anti-apoptotic activity through 
PI3K, but not through ERK, whereas H-Ras promoted hepatocyte 
survival through both ERK and PI3K. Thus, according to the results in 
article III and IV, we suggested that redox-activated ERK promoted 
survival through H-Ras in primary rat hepatocytes.
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CONCLUDING REMARKS 
We have demonstrated that in primary rat hepatocytes, CDK4 
activity was necessary for CDK2 nuclear translocation and proliferation, 
and that growth factor activation of p53-p21Cip1 was necessary for CDK4 
and CDK2 trafficking. Our results were in accordance with the notion 
that in cells without DNA damage, p53-p21Cip1 activation is a positive 
regulator of physiological cellular proliferation. In addition to regulation 
of cyclin D1, PI3K controlled proliferation through p53 induction. It also 
appeared that an additional growth factor signalling pathway was 
necessary, since ectopic expression of cyclin D1 and p21Cip1 was not 
sufficient for growth induction. 
Cytoplasmic retention of activated ERK remains a putative 
mechanism of carcinogen-induced growth inhibition and thus cell cycle 
progression. Although this was observed following both H2O2 and 
carcinogen (2-acetylaminofluorene) exposure, the former appeared to 
affect ERK differently, since it phosphorylated ERK by itself. From the 
cytoplasmic compartment, redox-activated ERK was able to mediate 
survival. Such signalling may possibly contribute to the carcinogenic 
development. Our results demonstrated that hepatocyte proliferation was 
H-Ras dependent, since K-Ras did not activate ERK. In addition, H-Ras 
promoted survival through both ERK and PI3K, whereas K-Ras 
mediated an anti-apoptotic activity through PI3K. 
For further experiments, this thesis pinpoints the following problems to 
be addressed: 
x Characterize the unknown signals, which are critical for 
hepatocyte cell cycle progression, in addition to cyclin D1 and 
p21Cip1 induction. 
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x Characterize if ectopically expressed p21Cip1 can recover the 
growth arrest in carcinogen-exposed hepatocytes. 
x Characterize the upstream activator of MEK following H2O2-
exposure.
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